Morges, Switzerland, February 4th 2022 – Biosensors International Group, Ltd. ("Biosensors" or the "Company"), a developer and manufacturer of innovative medical devices, announced today the enrollment of the first patient in the RISE™ SC study a single arm, prospective, multicenter First-in-Human trial to evaluate the acute safety and device success of the RISE™ SC coronary balloon when used as a dilatation device in the stenotic portion of a coronary artery or bypass graft in patients with Coronary Artery Disease. This trial is targeting CE-mark approval for the new RISE™ Semi-Compliant balloon (SCB). It will include 3 investigational centers in Switzerland led by Prof. Marco Roffi, Director of the Interventional Cardiology Unit at the University Hospital of Geneva, Switzerland and member of the ESC Committee for Practice Guidelines. The first case with this device was performed in the HVS of Sion. The first patient was a 78-year-old male with a lesion in the LAD. A 2.5x12 mm RISE™ SC balloon was used, and no complications were reported during the procedure.